FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308668146> ?p ?o ?g. }

• W4308668146 endingPage "1441" @default.
• W4308668146 startingPage "1436" @default.
• W4308668146 abstract "Four COVID-19 vaccines are currently approved for primary series vaccination in the United States under a Biologics License Application or authorized under an emergency use authorization (EUA) by the Food and Drug Administration (FDA), and recommended for primary series vaccination by the Advisory Committee on Immunization Practices (ACIP): 1) the 2- or 3-dose monovalent mRNA BNT162b2 (Pfizer-BioNTech, Comirnaty) COVID-19 vaccine; 2) the 2- or 3-dose monovalent mRNA mRNA-1273 (Moderna, Spikevax) COVID-19 vaccine; 3) the single-dose adenovirus vector-based Ad26.COV.S (Janssen [Johnson & Johnson]) COVID-19 vaccine; and 4) the 2-dose adjuvanted, protein subunit-based NVX-CoV2373 (Novavax) COVID-19 vaccine. The number of doses recommended is based on recipient age and immunocompromise status (1). For additional protection, FDA has amended EUAs to allow for COVID-19 booster doses in eligible persons (1). Because COVID-19 vaccines have demonstrated decreased effectiveness during the period when the Omicron variant (B.1.1.529) of SARS-CoV-2 predominated, bivalent booster doses (i.e., vaccine with equal components from the ancestral and Omicron strains) were considered for the express purpose of improving protection conferred by COVID-19 vaccine booster doses (2). During September-October 2022, FDA authorized bivalent mRNA vaccines for use as a booster dose in persons aged ≥5 years who completed any FDA-approved or FDA-authorized primary series and removed EUAs for monovalent COVID-19 booster doses (1). Pfizer-BioNTech and Moderna bivalent booster vaccines each contain equal amounts of spike mRNA from the ancestral and Omicron BA.4/BA.5 strains. After the EUA amendments, ACIP and CDC recommended that all persons aged ≥5 years receive 1 bivalent mRNA booster dose ≥2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or monovalent booster doses." @default.
• W4308668146 created "2022-11-14" @default.
• W4308668146 creator A5011431528 @default.
• W4308668146 creator A5016169182 @default.
• W4308668146 creator A5019036064 @default.
• W4308668146 creator A5020614173 @default.
• W4308668146 creator A5023379626 @default.
• W4308668146 creator A5024358117 @default.
• W4308668146 creator A5042321558 @default.
• W4308668146 creator A5044650094 @default.
• W4308668146 creator A5047253617 @default.
• W4308668146 creator A5051055046 @default.
• W4308668146 creator A5051548699 @default.
• W4308668146 creator A5052355289 @default.
• W4308668146 creator A5061113403 @default.
• W4308668146 creator A5064280673 @default.
• W4308668146 creator A5065477099 @default.
• W4308668146 creator A5066014283 @default.
• W4308668146 creator A5073559339 @default.
• W4308668146 creator A5078473867 @default.
• W4308668146 date "2022-11-11" @default.
• W4308668146 modified "2023-10-09" @default.
• W4308668146 title "Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022" @default.
• W4308668146 cites W4285590921 @default.
• W4308668146 cites W4302283217 @default.
• W4308668146 doi "https://doi.org/10.15585/mmwr.mm7145a2" @default.
• W4308668146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355612" @default.
• W4308668146 hasPublicationYear "2022" @default.
• W4308668146 type Work @default.
• W4308668146 citedByCount "57" @default.
• W4308668146 countsByYear W43086681462022 @default.
• W4308668146 countsByYear W43086681462023 @default.
• W4308668146 crossrefType "journal-article" @default.
• W4308668146 hasAuthorship W4308668146A5011431528 @default.
• W4308668146 hasAuthorship W4308668146A5016169182 @default.
• W4308668146 hasAuthorship W4308668146A5019036064 @default.
• W4308668146 hasAuthorship W4308668146A5020614173 @default.
• W4308668146 hasAuthorship W4308668146A5023379626 @default.
• W4308668146 hasAuthorship W4308668146A5024358117 @default.
• W4308668146 hasAuthorship W4308668146A5042321558 @default.
• W4308668146 hasAuthorship W4308668146A5044650094 @default.
• W4308668146 hasAuthorship W4308668146A5047253617 @default.
• W4308668146 hasAuthorship W4308668146A5051055046 @default.
• W4308668146 hasAuthorship W4308668146A5051548699 @default.
• W4308668146 hasAuthorship W4308668146A5052355289 @default.
• W4308668146 hasAuthorship W4308668146A5061113403 @default.
• W4308668146 hasAuthorship W4308668146A5064280673 @default.
• W4308668146 hasAuthorship W4308668146A5065477099 @default.
• W4308668146 hasAuthorship W4308668146A5066014283 @default.
• W4308668146 hasAuthorship W4308668146A5073559339 @default.
• W4308668146 hasAuthorship W4308668146A5078473867 @default.
• W4308668146 hasBestOaLocation W43086681461 @default.
• W4308668146 hasConcept C121332964 @default.
• W4308668146 hasConcept C12590561 @default.
• W4308668146 hasConcept C126322002 @default.
• W4308668146 hasConcept C1276947 @default.
• W4308668146 hasConcept C159047783 @default.
• W4308668146 hasConcept C162324750 @default.
• W4308668146 hasConcept C17744445 @default.
• W4308668146 hasConcept C178790620 @default.
• W4308668146 hasConcept C185592680 @default.
• W4308668146 hasConcept C187736073 @default.
• W4308668146 hasConcept C199539241 @default.
• W4308668146 hasConcept C203165030 @default.
• W4308668146 hasConcept C22070199 @default.
• W4308668146 hasConcept C2522874641 @default.
• W4308668146 hasConcept C2776620830 @default.
• W4308668146 hasConcept C2776957806 @default.
• W4308668146 hasConcept C2779134260 @default.
• W4308668146 hasConcept C3008058167 @default.
• W4308668146 hasConcept C3017489713 @default.
• W4308668146 hasConcept C32611913 @default.
• W4308668146 hasConcept C512399662 @default.
• W4308668146 hasConcept C524204448 @default.
• W4308668146 hasConcept C544153396 @default.
• W4308668146 hasConcept C71924100 @default.
• W4308668146 hasConceptScore W4308668146C121332964 @default.
• W4308668146 hasConceptScore W4308668146C12590561 @default.
• W4308668146 hasConceptScore W4308668146C126322002 @default.
• W4308668146 hasConceptScore W4308668146C1276947 @default.
• W4308668146 hasConceptScore W4308668146C159047783 @default.
• W4308668146 hasConceptScore W4308668146C162324750 @default.
• W4308668146 hasConceptScore W4308668146C17744445 @default.
• W4308668146 hasConceptScore W4308668146C178790620 @default.
• W4308668146 hasConceptScore W4308668146C185592680 @default.
• W4308668146 hasConceptScore W4308668146C187736073 @default.
• W4308668146 hasConceptScore W4308668146C199539241 @default.
• W4308668146 hasConceptScore W4308668146C203165030 @default.
• W4308668146 hasConceptScore W4308668146C22070199 @default.
• W4308668146 hasConceptScore W4308668146C2522874641 @default.
• W4308668146 hasConceptScore W4308668146C2776620830 @default.
• W4308668146 hasConceptScore W4308668146C2776957806 @default.
• W4308668146 hasConceptScore W4308668146C2779134260 @default.
• W4308668146 hasConceptScore W4308668146C3008058167 @default.
• W4308668146 hasConceptScore W4308668146C3017489713 @default.
• W4308668146 hasConceptScore W4308668146C32611913 @default.
• W4308668146 hasConceptScore W4308668146C512399662 @default.
• W4308668146 hasConceptScore W4308668146C524204448 @default.

• next